10-Q: Humana Reports Mixed Q2 Earnings Amid Strategic Shifts and Rising Regulatory Scrutiny

Humana Inc. reported a decline in second-quarter net income and diluted EPS, primarily due to valuation adjustments and impairment charges, while six-month results showed growth, as the company navigates membership shifts and an evolving regulatory landscape.

Summary

• Net income attributable to Humana for the three months ended June 30, 2025, was $545 million, or $4.51 per diluted common share, down from $679 million, or $5.62 per diluted common share, in the prior year.
• For the six months ended June 30, 2025, net income attributable to Humana increased to $1.789 billion, or $14.81 per diluted common share, up from $1.420 billion, or $11.74 per diluted common share, in the prior year.
• Total revenues for the three months ended June 30, 2025, increased 9.6% to $32.388 billion, and for the six months, increased 9.0% to $64.500 billion.
• The decline in Q2 net income and EPS was significantly impacted by $200 million in put/call valuation adjustments associated with non-consolidating minority interest investments, $32 million in impairment charges, and $29 million in charges related to value creation initiatives.
• The consolidated benefit ratio increased to 89.7% in Q2 2025 from 89.0% in Q2 2024, reflecting a shift in business mix and individual Medicare Advantage membership reduction.
• The consolidated benefit ratio for the six months ended June 30, 2025, decreased to 88.4% from 88.9% in the prior year, partly due to favorable workday impact in Q1 2025.
• Individual Medicare Advantage membership decreased by 388,300 members, or 6.9%, to 5,229,300 at June 30, 2025, due to the decision to exit certain unprofitable plans and counties.
• State-based contracts and other membership increased by 190,600 members, or 13.7%, to 1,582,900, driven by additional membership in Kentucky, Ohio, and Indiana.
• Medicare stand-alone PDP membership increased by 85,900 members, or 3.7%, to 2,427,100.
• Military services membership decreased by 1,370,400 members, or 23.0%, to 4,588,800.
• Net cash provided by operating activities was $1.602 billion for the six months ended June 30, 2025, relatively unchanged from $1.636 billion in the prior year.
• Net cash provided by investing activities was $661 million for the six months ended June 30, 2025, a significant improvement from net cash used of $1.416 billion in the prior year, primarily due to net proceeds from investment securities.
• The company issued $1.5 billion in new senior notes in March 2025 and used $577 million to repay maturing notes, with remaining proceeds for general corporate purposes.
• The revolving credit agreement was amended and restated in May 2025, increasing commitments from $2.642 billion to $5.0 billion, with $4.985 billion of remaining borrowing capacity at June 30, 2025.
• The company repurchased $100 million of common shares during the six months ended June 30, 2025, compared to $750 million in the prior year, with $2.8 billion remaining under the repurchase authorization.
• Debt to capitalization ratio was 40.7% as of June 30, 2025, well below the 60% financial covenant.
• The Medicare Part D coverage gap was eliminated effective January 1, 2025, by the Inflation Reduction Act of 2022, capping beneficiary out-of-pocket expenses at $2,000 and shifting more responsibility to the company, impacting seasonality of prescription costs.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While Q2 net income and EPS declined due to specific charges and valuation adjustments, the six-month results show strong growth in revenue, net income, and EPS. The company is actively managing its portfolio by exiting unprofitable businesses and expanding its credit facilities, indicating proactive strategic management. However, significant ongoing legal and regulatory challenges, particularly concerning Medicare Advantage risk adjustment and Star Ratings, introduce considerable uncertainty and potential future financial impacts.

Positives

• Total revenues increased by 9.6% for the three months and 9.0% for the six months ended June 30, 2025, demonstrating strong top-line growth.
• Net income attributable to Humana increased by 26.0% for the six months ended June 30, 2025, indicating improved profitability over the longer period.
• Diluted earnings per common share increased by 26.1% for the six months ended June 30, 2025.
• The consolidated benefit ratio decreased by 50 basis points for the six months ended June 30, 2025, suggesting improved underwriting profitability over the longer term.
• CenterWell segment revenues from primary care and pharmacy solutions businesses showed significant growth, with primary care external revenues up 59.3% in Q2 and 74.4% for 6 months.
• State-based contracts and Medicare stand-alone PDP businesses experienced membership growth, contributing to premium revenue increases.
• Net cash provided by investing activities significantly improved to $661 million for the six months ended June 30, 2025, from a net use of $1.416 billion in the prior year, driven by net proceeds from investment securities.
• The company successfully issued $1.5 billion in new senior notes, demonstrating access to capital markets.
• The revolving credit agreement was expanded to $5.0 billion, increasing liquidity and financial flexibility.
• The debt to capitalization ratio of 40.7% is well within the 60% financial covenant, indicating a healthy balance sheet.

Negatives

• Net income attributable to Humana decreased by 19.7% for the three months ended June 30, 2025, compared to the prior year.
• Diluted earnings per common share decreased by 19.8% for the three months ended June 30, 2025.
• The consolidated benefit ratio increased by 70 basis points for the three months ended June 30, 2025, indicating a decline in underwriting profitability for the quarter.
• The consolidated operating cost ratio increased by 20 basis points for both the three and six months ended June 30, 2025, suggesting decreased administrative spending efficiency.
• Individual Medicare Advantage membership declined by 388,300 members, or 6.9%, due to the decision to exit certain unprofitable plans and counties.
• Military services membership significantly decreased by 1,370,400 members, or 23.0%.
• Commercial fully-insured and ASO businesses were fully exited, resulting in a 100% membership decline in these segments.
• Investment income decreased by 8.7% for the three months and 8.5% for the six months ended June 30, 2025, primarily due to lower interest income on debt securities.
• Other expense, net, increased significantly by 263.6% for the three months and 207.6% for the six months ended June 30, 2025, largely due to put/call valuation adjustments associated with non-consolidating minority interest investments.
• Impairment charges of $32 million relating to indefinite-lived intangible assets were recorded for the three and six months ended June 30, 2025, with no comparable charges in the prior year.

Risks

• The Final RADV Rule, including the elimination of the Fee-for-Service Adjuster, and any related regulatory, industry or company reactions, the expansion of CMS's auditing efforts to include all eligible MA contracts, and the acceleration of RADV audits for PY 2018 through PY 2024, could each have a material adverse effect on results of operations, financial position, or cash flows.
• There is no assurance that the lawsuit filed against the United States Department of Health and Human Services and Xavier Becerra regarding the Final RADV Rule will prevail.
• Internal compliance reviews related to risk coding and data submissions may identify errors and require corrections to CMS, which could be material and have an adverse effect on results of operations, financial position, or cash flows.
• The loss of state-based Medicaid contracts or significant changes in these programs (e.g., reductions in premium payments, regulatory restrictions on profitability, or increases in member benefits without corresponding premium increases) may have a material adverse effect.
• Ongoing litigation, including the putative stockholder class action and parallel stockholder derivative actions alleging false or misleading statements and breach of fiduciary duty, could result in unspecified compensatory damages, attorneys' fees, and corporate governance reforms.
• A DOJ complaint in partial intervention related to a qui tam lawsuit alleges civil violations concerning non-commission payments to broker partners and marketing of Medicare Advantage plans to under-65 beneficiaries, seeking damages and penalties under the federal False Claims Act, which could lead to additional federal securities law and stockholder derivative allegations.
• Reviews by various state insurance and health care regulatory authorities and other state and federal regulatory authorities could result in additional fines, sanctions, or required changes to business practices.
• The outcome of any current or future litigation or governmental or internal investigations cannot be accurately predicted, and any resulting judgments, penalties, fines, or other sanctions could be substantial and materially adverse.
• Adverse changes in the company's credit rating (currently BBB by S&P and Baa2 by Moody's) may increase interest rates on debt and impact future credit availability.
• The company's holding company structure means it is dependent on dividends and administrative expense reimbursements from subsidiaries, most of which are subject to regulatory restrictions on dividend payments.
• There is a continuing risk that future declines in fair value of investment securities may occur and material realized losses from sales or credit allowances may be recorded in future periods, despite the current belief that unrealized losses will be recovered.

Future Outlook

The company expects to incur additional charges in 2025 related to value creation initiatives. The elimination of the Medicare Part D coverage gap, effective January 1, 2025, is anticipated to reduce out-of-pocket costs for beneficiaries and impact plan liabilities, resulting in more level prescription costs throughout the year. The company intends to continue its strategy of offering affordable healthcare combined with a positive consumer experience in growing markets, focusing on its integrated care delivery model for long-term membership and earnings growth. CMS's expanded and expedited RADV audits for PY 2018 through PY 2024 are expected to be completed by early 2026, with potential material adverse effects.

Management Comments

• Our strategy is to offer our members affordable health care combined with a positive consumer experience in growing markets.
• At the core of this strategy is our integrated care delivery model, which unites quality care, high member engagement, and sophisticated data analytics.
• We believe this strategy is positioning us for long-term growth in both membership and earnings.
• We remain committed to working alongside CMS to promote the integrity of the MA program as well as affordability and cost certainty for our members.
• It is critical that MA plans are paid accurately and that payment model principles, including the application of a FFS Adjuster, are in accordance with the requirements of the Social Security Act, which, if not implemented correctly could have a material adverse effect on our results of operations, financial position, or cash flows.
• We take seriously our obligations to comply with applicable regulatory requirements and laws, and will vigorously defend against these allegations.

Industry Context

The healthcare industry, particularly the Medicare Advantage and Part D segments, is undergoing significant regulatory changes, notably from the Inflation Reduction Act of 2022, which impacts benefit design and cost-sharing. The Centers for Medicare and Medicaid Services (CMS) is increasing scrutiny through expanded and expedited Risk-Adjustment Data Validation (RADV) audits, creating a challenging operating environment for health plans. Humana's strategic decision to exit unprofitable Medicare Advantage plans and commercial businesses reflects a broader industry trend of companies optimizing portfolios in response to competitive pressures and regulatory shifts. The company's focus on value-based care and integrated health services through its CenterWell segment aligns with the industry's move towards more coordinated and cost-effective care delivery models.

Legal Proceedings

• A lawsuit was filed against the United States Department of Health and Human Services and Xavier Becerra in his official capacity as Secretary, seeking a determination that the Final RADV Rule violates the Administrative Procedure Act and should be set aside. This suit was dismissed on July 18, 2025, and refiled on July 21, 2025.
• A putative stockholder class action, 'In re Humana Inc. Securities Litigation,' was filed in June 2024, alleging false or misleading statements in SEC filings and financial markets regarding financial performance, medical costs, and Star Ratings in the Medicare Advantage business.
• Parallel stockholder derivative actions ('Silva v. Broussard,' 'Spikes v. Broussard,' 'Noble v. Broussard,' 'Combs v. Broussard,' and 'Nicolaou v. Broussard') were filed between July 2024 and March 2025, alleging breach of fiduciary duty by current and former directors and executive officers based on the same claimed acts and omissions as the federal securities law case.
• On May 1, 2025, the Department of Justice filed a complaint in partial intervention related to a qui tam lawsuit ('United States of America ex. rel. Andrew Shea v. eHealth, Inc., et al.'), alleging civil violations concerning non-commission payments to three call center broker partners and marketing of Medicare Advantage plans to Medicare-eligible beneficiaries under the age of 65.
• A lawsuit was filed on October 18, 2024, against the United States Department of Health and Human Services, Centers for Medicare and Medicaid Services, Xavier Becerra, and Chiquita Brooks-LaSure, seeking a determination that they violated the Administrative Procedure Act in administering the Medicare Advantage and Part D Star Ratings program. This case was dismissed on July 18, 2025, and refiled on July 21, 2025.
• The company is subject to ongoing reviews and investigations by various state insurance and health care regulatory authorities and other state and federal regulatory authorities, which could result in fines or sanctions.
• The company is involved in various other lawsuits arising in the ordinary course of business, including employment matters, medical malpractice claims, bad faith claims, personal injury claims, provider disputes, and challenges to subrogation practices.
• As a government contractor, the company may be subject to false claims litigation, such as qui tam lawsuits, alleging false claims or overpayments from the government.

Stakeholder Impact

• Shareholders: Experienced a decline in Q2 EPS but growth in 6M EPS. The company continues share repurchases and dividend payments. However, ongoing legal proceedings and regulatory risks could impact future share price and returns.
• Members/Patients: The company's integrated care delivery model aims to improve health outcomes and affordability. Changes to Medicare Part D due to the Inflation Reduction Act are anticipated to reduce out-of-pocket costs for beneficiaries.
• Employees: The company is undertaking 'workforce optimization' as part of its value creation initiatives, which has resulted in severance charges, indicating potential job impacts.
• Providers: The company relies on providers for diagnosis data submissions and is expanding value-based relationships. Regulatory audits (RADV) scrutinize provider coding practices.
• Government/Regulators (CMS, DOJ): The company is engaged in significant legal disputes and is subject to increased scrutiny and audits regarding Medicare Advantage programs, risk adjustment, and marketing practices.

Next Steps

• Continue to incur additional charges in 2025 related to value creation initiatives.
• CMS will conduct RADV audits for all eligible MA contracts for each payment year in all newly initiated audits and expedite completion for PY 2018 through PY 2024 by early 2026.
• The company will vigorously defend against allegations in the putative stockholder class action and parallel stockholder derivative actions.
• The company will vigorously defend against the DOJ's complaint in partial intervention related to the qui tam lawsuit.
• The company refiled its lawsuit against HHS/CMS regarding Medicare Advantage and Part D Star Ratings program on July 21, 2025, seeking to declare certain policies unlawful and recalculate 2025 Star Ratings.
• The Rule 10b5-1 Repurchase Plan for senior notes will continue until August 29, 2025.

Key Dates

Recommendation

Humana's Q2 2025 results show a decline in net income and EPS, primarily due to specific, disclosed valuation adjustments and impairment charges. However, the six-month performance indicates overall revenue and earnings growth. The company is actively pursuing strategic initiatives, including exiting unprofitable plans and implementing cost efficiencies, which are positive long-term signals. Despite these efforts, the company faces substantial and ongoing legal and regulatory challenges, particularly related to Medicare Advantage risk adjustment and Star Ratings, which introduce significant uncertainty and potential financial liabilities. The mixed short-term financial performance, coupled with the high regulatory risk, suggests a 'hold' recommendation, as the company navigates a complex environment where future outcomes are highly dependent on the resolution of these external pressures and the successful execution of its strategic adjustments.

Keywords

Healthcare, Insurance, Medicare Advantage, Medicare Part D, Medicaid, Health Services, CenterWell, SEC Filing, 10-Q, Financial Results, Earnings, Membership, Regulatory Risk, Litigation, Capital Structure, Debt, Risk Adjustment